Latest Information Update: 13 Feb 2017
At a glance
- Originator Chong Kun Dang
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 13 Feb 2017 Chong Kun Dang Pharmaceutical plans a phase I trial for an Undefined indication (NCT03034486)
- 25 Jan 2017 Preclinical trials in Undefined indication in South Korea (unspecified route)